Enoxaparin Sodium

Enoxaparin is a **low molecular weight heparin (LMWH)** used primarily for the prophylaxis and treatment of thromboembolic disease, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and feline aortic thromboembolism (FATE). Compared to standard unfractionated heparin (UFH), LMWHs like enoxaparin offer a more predictable pharmacokinetic profile and preferentially inhibit Factor Xa over thrombin. This selective action means that standard coagulation tests (like aPTT) are not significantly prolonged, making hemorrhage less likely but also making monitoring more specialized. **Clinical Pearls:** * While LMWHs are theoretically safer and more predictable than UFH in humans, their rapid clearance in dogs and cats necessitates frequent subcutaneous dosing (often every 6 hours). * This frequent dosing schedule, combined with the high cost of the medication, can make long-term management challenging in veterinary medicine, particularly for large dogs or horses. * Recent studies in cats suggest that anti-Xa activity levels may not perfectly correlate with actual antithrombotic efficacy, complicating therapeutic monitoring.

กลไกการออกฤทธิ์: Enoxaparin exerts its anticoagulant effect by binding to and accelerating the activity of **antithrombin III (ATIII)**. * The enoxaparin-ATIII complex preferentially inhibits **Factor Xa** (→ blocking the conversion of prothrombin to thrombin in the coagulation cascade). * Because of its smaller molecular size compared to unfractionated heparin, enoxaparin has minimal impact on **thrombin (Factor IIa)**. * This selective anti-Xa activity prevents clot formation and extension without significantly altering standard clotting times (TT or aPTT).

ข้อมูลอ้างอิงยาของ VetSheet มีไว้สำหรับสัตวแพทย์ผู้มีใบอนุญาตเพื่อช่วยในการตัดสินใจทางคลินิก ไม่ใช่สิ่งทดแทนการวินิจฉัยของผู้เชี่ยวชาญหรือฉลากล่าสุดของผู้ผลิต